AUGUST 23, 2012 BENEFIT PREVIEW PARTY      AUGUST 24-26, 2012 OPEN TO THE PUBLIC

The American Craft Exposition (ACE) is committed to supporting breast and ovarian cancer research. Ovarian cancer is called the “silent” killer because symptoms are easy to dismiss and the disease is often diagnosed too late for effective treatment. Beginning in 2011, ACE will support pioneering research being conducted at NorthShore that is already showing promising results in preventing ovarian cancer in at-risk women. Below is a list of physician-scientists and projects funded by ACE.

2011

Development of a Progestin-Based Pharmacologic Approach for the Effective Prevention of Ovarian Cancer

2010

Clincial Research Coordinator for breast and ovarian cancer reserach at NorthShore University HealthSystem

2009

Katherine Yao, MD

Funds benefit a two year Breast Cancer Research Fellowship

2008

Manjari Dimri, MD

“Identification of Oncologic Lesions Involved in Invasive and Refractory Breast Cancer"

San Ming Wang, MD

“Identifying New Breast Cancer Susceptibility Genes”

2007

Dr. Jean Hurteau

“Progestin and Eicosanoid combination for chemoprevention of ovarian cancer.”

C. B. Gurumurthy, PhD

“hEcd, a novelmarker for breast cancer.”

J. Raja Srikumar, PhD

“Combinatorial targeting of ErbB2-HSPop towards treatment of ErbB2-related breast cancer tumors.”

2006 

Sofia F. Garcia, Ph.D.

Real-time Symptom Monitoring via Computer Telephony in Patients with Advanced Breast Cancer

Xijin Ge, Ph.D.

Bioinformatics study on BRCA1 Transcriptional Regulation Mechanisms

Gustavo Rodriguez, M.D.

Development of a Progestin-Based Chemopreventive Agent for Epithelial Ovarian Cancer

2005 

Javier Menendez, M.D.

Effects of dietary fatty acids in Her-2/neu (erbB-2) oncogene-induced breast tumorigenesis and trastuzumab (Herceptin™) efficacy

David J. Winchester, M.D.

DNA microarray analysis of multicentric breast cancers

2004

Ruth Lupu, M.D.

Characterization of Heregulin-Induced Activation of HER-2: As A New Molecular target in Breast Cancer

Ruth Lupu, M.D.

A Possible Prognostic and Therapeutic Value of Cyr61/αvβ3 Integrin

2003 

Javier Menendez, M.D.

Pharmacological Inhibition of Fatty Acid Synthase:A New Therapeutic Approach in Her-2/neu-Overexpressing Breast Cancer

Prem K. Seth, Ph.D.

Gene Therapy for Breast Cancer: Targeting Mutant p53 and TGFβ with Replicating Adenoviruses

2002

Joseph Bass, M.D., Ph.D.

Regulation of Receptor Kinase Protooncogene Activity in Breast Cancer Cells

Cheikh Menaa, Ph.D.

Cellular and Molecular Mechanism of Osteoclast Formation and Bone Metastasis Induced by Breast Cancer

David J. Winchester, M.D.

Endoscopic, Cytologic, and Molecular Analysis of Nipple Aspirates in Women.  

Susan E. Yount, Ph.D.

Quality of Breast Cancer Care

2001 

Karin Klein, Ph.D.

Identifying the Genetic factors that Prevent Tumor Growth in Mammary Tissues (Project not completed due to relocation of Thor lab)

Stuart Lind, M.D.

Effects of Coformycin and Adenosine Upon Human Breast Cancer Cells

Douglas Merkel, M.D.

erbB-2: Clonality and Progression in Recurrence and Metastases
[Publication: Edgerton SM, Moore D, Merkel D, Thor AD: erbB-2 (HER-2) and Breast Cancer Progression.
Applied Immunohistochemistry & Molecular Morphology 2003; 11(3):214-21.]

XiaoHe Yang, M.D.

Breast Cancer Selective and DNA Damage Inducible Caspase 3 Mediated Gene Therapy
A Model of “Tissue Specific and Synchronized Double Hit” Cancer Therapy